2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

carcinoma cells

" in MedChemExpress (MCE) Product Catalog:

382

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

3

Biochemical Assay Reagents

16

Peptides

1

MCE Kits

20

Inhibitory Antibodies

141

Natural
Products

12

Isotope-Labeled Compounds

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119425
    Razoxane

    ICRF 159

    		 Topoisomerase Cancer
    Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC) .
    Razoxane
  • HY-P99023
    Girentuximab

    G250; cG250

    		 Carbonic Anhydrase Cancer
    Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
    Girentuximab
  • HY-100746
    STF-62247
    1 Publications Verification

    		 Autophagy Cancer
    STF-62247 is an autophagy inducer that selectively cytotoxic to VHL-deficient renal cell carcinoma (IC50 of 0.625 μM and 16 μM in RCC4 and RCC4/VHL cells, respectively) .
    STF-62247
  • HY-P99161
    Tilvestamab

    BGB149

    		 TAM Receptor Cancer
    Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas .
    Tilvestamab
  • HY-161854
    LASSBio-1911

    		HDAC Cancer
    LASSBio-1911 is a potent inhibitor of HDAC6. LASSBio-1911 shows antitumor in hepatocellular carcinoma (HCC) cells with minimal on normal cells .
    LASSBio-1911
  • HY-121532
    (-)-Rasfonin

    		Ras Apoptosis Autophagy Cancer
    (-)-Rasfonin is a fungal secondary metabolite and inhibits small G proteins Ras. (-)-Rasfonin induces apoptosis, necrosis and autophagy in ACHN cells (a renal carcinoma cell line) .
    (-)-Rasfonin
  • HY-119320
    Ethimidine

    Aethimidinum

    		 Others Cancer
    Ethimidine (Aethimidinum) can reduce the blood serum free SH (sulfhydryl) in in rats previously transplanted with sarcoma or carcinoma cells .
    Ethimidine
  • HY-147426
    Zifcasiran

    ADS-007; ARO HIF2

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    Zifcasiran is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran shows antitumor activities and can be used in advanced renal cell carcinoma research .
    Zifcasiran
  • HY-147426A
    Zifcasiran sodium

    ADS-007 sodium; ARO HIF2 sodium

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    Zifcasiran sodium is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran sodium shows antitumor activities and can be used in advanced renal cell carcinoma research .
    Zifcasiran sodium
  • HY-19412
    DMS-612

    NSC-281612

    		 Others Cancer
    DMS-612 (NSC-281612) is an alkylating agent with anti-renal cell carcinoma activity. DMS-612 can be used in cancer research .
    DMS-612
  • HY-168067
    CDK-IN-14

    		CDK Caspase Apoptosis Cancer
    CDK-IN-14 (B34) is a CDK2 inhibitor (IC50=0.097 μM) with anti-hepatocellular carcinoma activity. CDK-IN-14 blocks the cell cycle of HepG-2 cancer cells through a caspase-mediated mechanism and induces apoptosis .
    CDK-IN-14
  • HY-N2779
    8-Lavandulylkaempferol

    		Others Cancer
    8-Lavandulylkaempferol is a flavonoid that can be isolated from Sophora flaWescens. 8-Lavandulylkaempferol exhibits cytotoxic activity against the KB epidermoid carcinoma cell line with an IC50 of 15.1 μg/mL .
    8-Lavandulylkaempferol
  • HY-P99461
    Barecetamab

    ISU-104

    		 EGFR Cancer
    Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
    Barecetamab
  • HY-155377
    PLK1/p38γ-IN-1

    		Polo-like Kinase (PLK) p38 MAPK Cancer
    PLK1/p38γ-IN-1(compound 14) is a multitarget inhibitors ofPLK1andp38γ. PLK1/p38γ-IN-1inhibits the growth of human hepatocellular carcinoma and hepatoblastoma cells in vitro .
    PLK1/p38γ-IN-1
  • HY-155785
    MTP

    		Apoptosis Autophagy Reactive Oxygen Species JAK Cancer
    MTP is a PKM2 inhibitor. MTP induces cancer cell apoptosis by modulating caspase-3 activation. MTP induces autophagy and increases ROS generation. MTP also inhibits JAK2 signaling. MTP can be used for research of oral squamous cell carcinoma .
    MTP
  • HY-149063
    Antitumor agent-92

    		Apoptosis Cancer
    Antitumor agent-92, an Icaritin (HY-N0678) derivative, causes arrest at the G0/G1 phase in the cell cycle and induces cell apoptosis. Antitumor agent-92 has the potential for hepatocellular carcinoma (HCC) research .
    Antitumor agent-92
  • HY-17473
    Embelin
    4 Publications Verification

    Embelic acid; Emberine; NSC 91874

    		 IAP NF-κB Apoptosis Autophagy Cancer
    Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .
    Embelin
  • HY-W195984
    Z57346765
    1 Publications Verification

    		 Others Cancer
    Z57346765 is a PGK1-specific inhibitor that reduces the activity of metabolic enzymes in PGK1 glycolysis and inhibits PGK1-dependent cell proliferation. Z57346765 exerts inhibitory effects against clear cell renal cell carcinoma (KIRC) .
    Z57346765
  • HY-106364
    Peplomycin

    Bleomycin PEP; Pepleomycin

    		 Antibiotic Cancer
    Peplomycin (Bleomycin PEP; Pepleomycin) is an antibiotic analogue of Bleomycin (HY-108345), with high antitumor effect and less pulmonary toxicity. Peplomycin induce apoptosis in oral squamous carcinoma cell line SSCKN cells and pulmonary fibrosis in rats .
    Peplomycin
  • HY-119198
    NSC745885

    		Apoptosis Histone Methyltransferase Cancer
    NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers .
    NSC745885
  • HY-N12960
    Artobiloxanthone

    		Apoptosis Bcl-2 Family Caspase COX MMP STAT Cancer
    Artobiloxanthone (Compound AA3) exhibits antitumor activity, particularly against oral squamous cell carcinoma (OSCC). Artobiloxanthone inhibits Akt/mTOR pathway and STAT3 pathway, inhibits proliferation of SAS and T.Tn (with IC50 of 11 and 22 μM), and inhibits the cancer cell migration. Artobiloxanthone arrests cell cycle at S phase, and induces apoptosis in OSCC cells through activation of caspase 3/9 .
    Artobiloxanthone
  • HY-17473R
    Embelin (Standard)

    		IAP NF-κB Apoptosis Autophagy Cancer
    Embelin (Standard) is the analytical standard of Embelin. This product is intended for research and analytical applications. Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .
    Embelin (Standard)
  • HY-P99287
    Elsilimomab

    B-E8; Anti-IL-6 MAB B-E8; Anti-Human IL6 Recombinant Antibody

    		 Interleukin Related Inflammation/Immunology Cancer
    Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
    Elsilimomab
  • HY-148260
    KRAS G12D inhibitor 16

    		Ras Cancer
    KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC50 value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .
    KRAS G12D inhibitor 16
  • HY-B1247
    Protoporphyrin IX
    10+ Cited Publications

    		 Endogenous Metabolite Others
    Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX
  • HY-P99933
    Eftilagimod alfa

    IMP321; LAG-3Ig

    		 LAG-3 Cancer
    Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .
    Eftilagimod alfa
  • HY-149677
    ZK53

    		Mitochondrial Metabolism Cancer
    ZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP) (EC50: 1.37?μM for α-casein hydrolysis by HsClpP). ZK53 is is inactive toward bacterial ClpP proteins. ZK53 induces apoptosis in H1703, H520 and SK-MES-1 cells. ZK53 induces dysregulation of mitochondrial functions in lung squamous cell carcinoma (LUSC) cells. ZK53 inhibits tumor growth in H1703 xenograft mouse model .
    ZK53
  • HY-101246
    RPI-1

    		RET Cancer
    RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .
    RPI-1
  • HY-50767
    Palbociclib
    Maximum Cited Publications
    154 Publications Verification

    PD 0332991

    		 CDK Cancer
    Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib
  • HY-50767B
    Palbociclib dihydrochloride

    PD-0332991 dihydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) dihydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib dihydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib dihydrochloride
  • HY-50767C
    Palbociclib hydrochloride
    Maximum Cited Publications
    154 Publications Verification

    PD-0332991 hydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib hydrochloride
  • HY-147187
    MNK8

    		STAT Apoptosis Bcl-2 Family Survivin Cancer
    MNK8 is a potent STAT3 (signal transducer and activator of transcription 3) inhibitor. MNK8 inhibits STAT3 activation and reduced its DNA binding ability. MNK8 shows good growth inhibition against hepatocellular carcinoma (HCC) cells. MNK8 induces apoptosis in HCC cells. MNK8 reduces prosurvival proteins expression and migration/invasion of HCC cells .
    MNK8
  • HY-P99406
    Petosemtamab

    MCLA 158

    		 EGFR Cancer
    Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
    Petosemtamab
  • HY-50767A
    Palbociclib monohydrochloride
    Maximum Cited Publications
    154 Publications Verification

    PD 0332991 monohydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib monohydrochloride
  • HY-A0065
    Palbociclib isethionate
    Maximum Cited Publications
    154 Publications Verification

    PD 0332991 isethionate

    		 CDK Cancer
    Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib isethionate
  • HY-50767D
    Palbociclib orotate

    PD 0332991 orotate

    		 CDK Cancer
    Palbociclib (PD 0332991) orotate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib orotate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib orotate can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib orotate
  • HY-162934
    TFCP2L1-IN-1

    		Others Cancer
    TFCP2L1-IN-1 is a specific small molecule targeting TFCP2L1’s active domain with anti-cancer activity. TFCP2L1-IN-1 synergizes with Sorafenib (HY-10201) to induce Apoptosis and reduces cell proliferation, invasion, metastasis, clonal formation and sphere-forming capacity in hepatocellular carcinoma cells .
    TFCP2L1-IN-1
  • HY-P99463
    Batiraxcept

    AVB-S6-500

    		 TAM Receptor Cancer
    Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .
    Batiraxcept
  • HY-13559A
    Atiprimod dimaleate

    Azaspirane dimaleate; SKF 106615-12 dimaleate; SKF 106615A12 dimaleate

    		 Apoptosis Caspase STAT Interleukin Related
    Atiprimod (Azaspirane) (dimaleate) is an anti-proliferative and anti-angiogenic agent that inhibits proliferation of cancer cell lines. Atiprimod (dimaleate) also induces Apoptosis and activates both caspase-9 and caspase-3 in T84 colon carcinoma cells. Atiprimod (dimaleate) inhibits both bFGF and VEGF induced proliferation and migration of human umbilical vein endothelial cells, resulting in disruption of cord formation. Atiprimod (dimaleate) reduces production of IL-6, VEGF and inhibits activation of Stat3 .
    Atiprimod dimaleate
  • HY-119906
    Conglobatin

    FW-04-806

    		 HSP Apoptosis Cancer
    Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .
    Conglobatin
  • HY-118762
    KGP94

    		Cathepsin Cancer
    KGP94 is a selective inhibitor of cathepsin L with an IC50 of 189 nM . KGP94 inhibits migration and invasion of metastatic carcinoma and shows low cytotoxicity (GI50=26.9 µM) against various human cell lines .
    KGP94
  • HY-111458
    GSK2643943A
    5 Publications Verification

    		 Deubiquitinase Cancer
    GSK2643943A is a deubiquitinating enzyme (DUB) inhibitor targeting USP20. GSK2643943A has affinity with an IC50 of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC) .
    GSK2643943A
  • HY-50767R
    Palbociclib (Standard)

    		CDK Cancer
    Palbociclib (Standard) is the analytical standard of Palbociclib. This product is intended for research and analytical applications. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
    Palbociclib (Standard)
  • HY-150190
    F5446

    		Histone Methyltransferase Apoptosis Cancer
    F5446 (Compound 1) is a selective small molecule inhibitor of SUV39H1 methyltransferase. F5446 decreases H3K9me3 deposition at the FAS promoter, increases Fas expression and increases colorectal carcinoma cell sensitivity to FasL-induced apoptosis in vitro. F5446 suppresses human colon tumor xenograft growth in vivo .
    F5446
  • HY-P10607
    IALYLQQNW

    		EBV Cancer
    IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .
    IALYLQQNW
  • HY-12204
    PFK-015
    3 Publications Verification

    		 Autophagy Metabolic Disease Inflammation/Immunology Cancer
    PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC) .
    PFK-015
  • HY-P99032
    Monalizumab
    2 Publications Verification

    IPH2201

    		 Checkpoint Kinase (Chk) IFNAR Inflammation/Immunology Cancer
    Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
    Monalizumab
  • HY-153863
    MS934

    		MEK Cancer
    MS934 is a novel improved VHL-recruiting MEK 1/2 degrader. MS934 has anti-proliferation potency at inhibiting the growth of HT-29 cells with a GI50 value of 0.023 μM. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma .
    MS934
  • HY-B0986
    Hexylresorcinol

    4-Hexylresorcinol

    		 Parasite Bacterial Apoptosis Glucosidase Endogenous Metabolite Infection Metabolic Disease Cancer
    Hexylresorcinol (4-Hexylresorcinol) is a natural compound found in plants with antimicrobial, anthelmintic, antiseptic and antitumor activities. Hexylresorcinol can induce apoptosis in squamous carcinoma cells. Hexylresorcinol is a reversible and noncompetitive inhibitor of α-glucosidase. Hexylresorcinol has protective effects against oxidative DNA damage .
    Hexylresorcinol
  • HY-151341
    HIF-1/2α-IN-1

    		HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-1/2α-IN-1 is an orally active HIF-2α inhibitor. HIF-1/2α-IN-1 inhibits HIF-2α activity with an IC50 value of 0.92 μM. HIF-1/2α-IN-1 also can decrease HIF-1α levels. HIF-1/2α-IN-1 can be used for the research of clear cell renal cell carcinoma (ccRCC) .
    HIF-1/2α-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: